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Mercaptopurine versus placebo to prevent recurrence of 
Crohn’s disease after surgical resection (TOPPIC): 
a multicentre, double-blind, randomised controlled trial
Craig Mowat, Ian Arnott, Aiden Cahill, Malcolm Smith, Tariq Ahmad, Sreedhar Subramanian, Simon Travis, John Morris, John Hamlin, 
Anjan Dhar, Chuka Nwokolo, Cathryn Edwards, Tom Creed, Stuart Bloom, Mohamed Yousif, Linzi Thomas, Simon Campbell, Stephen J Lewis, 
Shaji Sebastian, Sandip Sen, Simon Lal, Chris Hawkey, Charles Murray, Fraser Cummings, Jason Goh, James O Lindsay, Naila Arebi, Lindsay Potts, 
Aileen J McKinley, John M Thomson, John A Todd, Mhairi Collie, Malcolm G Dunlop, Ashley Mowat, Daniel R Gaya, Jack Winter, 
Graham D Naismith, Holly Ennis, Catriona Keerie, Steff Lewis, Robin J Prescott, Nicholas A Kennedy, Jack Satsangi, for the TOPPIC Study Group*
Summary [A: we only include primary and safety data in the Summary and so it has been edited 
accordingly]
Background Up to 60% of patients with Crohn’s disease need intestinal resection within the first 10 years of diagnosis, 
and postoperative recurrence is common. We investigated whether mercaptopurine can prevent or delay postoperative 
clinical recurrence of Crohn’s disease.
Methods We did a randomised, placebo-controlled, double-blind trial at 29 UK secondary and tertiary hospitals of 
patients (aged >16 years in Scotland or >18 years in England and Wales) who had a confirmed diagnosis of Crohn’s 
disease and were undergoing [A: or had undergone? (the inclusion criteria in the methods section state that patients 
had undergone intestinal resection in the previous 3 months)] intestinal resection. Patients were randomly assigned 
(1:1) by a computer-generated web-based randomisation system to [A: oral?]daily mercaptopurine at a dose of 1 mg/kg 
body weight rounded to the nearest 25 mg or placebo; patients with low thiopurine methyltransferase activity received 
half the normal dose. Patients and their carers and physicians were masked to the treatment allocation. Patients were 
followed up for 3 years. The primary endpoint was a composite of clinical recurrence of Crohn’s disease (Crohn’s 
Disease Activity Index >150 plus 100 point increase in score) and the need for anti-inflammatory rescue treatment or 
primary surgical intervention. Primary and safety analyses were by intention to treat. Subgroup analyses by smoking 
status, previous thiopurines, previous infliximab or methotrexate, previous surgery, duration of disease, or age at 
diagnosis were also done. This trial is registered with the International Standard Randomised Controlled Trial 
Register (ISRCTN89489788) and the European Clinical Trials Database (EudraCT number 2006-005800-15).
Findings Between June 6, 2008, and April 23, 2012, 240 patients with Crohn’s disease were randomly assigned: 128 to 
mercaptopurine and 112 to placebo. All patients received at least one dose of study drug, and no randomly assigned 
patients were excluded from the analysis. 16 (13%) of patients in the mercaptopurine group versus 26 (23%) patients 
in the placebo group reached the primary endpoint (adjusted hazard ratio [HR] 0·535 [A: please give to 2 dp], 95% CI 
0·27–1·06; p=0·07; unadjusted HR 0·53, 95% CI 0·28–0·99; p=0·046). In a subgroup analysis, three (10%) of 
29 smokers in the mercaptopurine group and 12 (46%) of 26 in the placebo group reached the primary endpoint 
(HR 0·13, 95% CI 0·04–0·46), compared with 13 (13%) of 99 non-smokers in the mercaptopurine group and 14 (16%) 
of 86 in the placebo group (0·90, 0·42–1·94; pinteraction[A: correct?]=0·018). None of the other planned subgroup analyses 
were significant (previous thiopurines, previous infliximab or methotrexate, previous surgery, duration of disease, or 
age at diagnosis). The incidence and types of adverse events were similar in the mercaptopurine and placebo groups. 
One patient on placebo died of ischaemic heart disease. Adverse events caused discontinuation of treatment in 
39 (30%) of 128 patients in the mercaptopurine group versus 41 (37%) of 112 in the placebo group.
Interpretation [A: this section should be an interpretation of the key results, not a repetition of the main findings. 
Please provide a sentence or two to explain the importance of these findings (eg, should mercaptopurine be 
recommended for prevention of post-op recurrence? What future studies are needed?)]
Funding Medical Research Council.
Copyright © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY license
Introduction 
Crohn’s disease is a chronic, relapsing inflammatory 
bowel disease. Estimates of the frequency of surgical 
resection in Crohn’s disease vary. Historical data suggest 
that up to 60% of patients need a major abdominal 
resection within 10 years of diagnosis.1 [A: ref for 60% 
correct?] However, more recent population-based data 
suggest this figure is as low as 29% at 7 years.2 [A: ref 1 
[A: We have edited your paper to avoid repetition, enhance readability, 
reduce length, and achieve consistency with Lancet style. Please check 
that all drug names are the rINNs (recommended international non-
proprietary names) where possible, and please ensure that the dose, 
route, and frequency of administration are correct. Please note that we 
try to keep use of abbreviations to a minimum so I have spelt out 
where necessary]
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deleted because I presumed this is the older data] 
Postoperative recurrence is common within 2 years, in 
the form of endoscopic signs (72–98% of patients) or 
clinical symptoms (37–70%), with re-operation rates 
accumulating at 5% of patients per year.3,4 [A: please 
clarify—do you mean “the proportion of patients needing 
surgery increasing by 5% per year” (rather than “with 5% 
of patients per year needing surgery”)?]
Strategies to prevent or delay postoperative recurrence of 
Crohn’s disease are of major clinical importance. However, 
there is a paucity of evidence to support any particular 
drug treatment strategy.5,6 Azathioprine and 
mercaptopurine have an established role in inducing 
remission, and in the maintenance of medically induced 
remission, in patients with Crohn’s disease. These drugs 
are recommended in treatment algorithms for patients at 
high risk of postoperative relapse,4 but the evidence to 
support this, and the evidence that clinical parameters can 
[A: OK? or “might”?] predict patients at high risk of relapse, 
is weak. A meta-analysis7 showed that efficacy data for 
thiopurines in this setting were inconclusive and, aside 
from smoking, there were no consistent predictors of 
postoperative relapse. A Cochrane review8 also concluded 
that the evidence supporting thiopurines for the reduction 
of endoscopic and clinical recurrence was marked by [A: 
please clarify “evidence…was insufficient because of”?] the 
small numbers of patients included and flawed study 
designs. The value of thiopurine metabolites in patients 
with Crohn’s disease is unknown.9 [A: is this ref correct? I 
cannot find mention of thiopurine metabolites in the 
reference] More recently, [A: than what?] the role of 
biological treatments in this specialty has received 
substantial attention. After smaller randomised studies of 
infliximab,9,10 [A: what did these trials show that is relevant 
to the POCER study?] findings from the POCER study11 
showed that targeted escalation of immune-modulatory 
treatment (ie, thiopurines followed by adalimumab) in 
patients with early endoscopic evidence of recurrence 
might [A: OK? or “seems to”?] delay subsequent 
endoscopic, although not clinical, recurrence.
We therefore aimed to establish whether 
mercaptopurine, compared with placebo, can prevent or 
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Research in context
Evidence before this study
The first randomised controlled trial of thiopurines for prevention 
of postoperative Crohn’s disease was published in 2000 [A: what 
did it show?]. However, uncertainty remains about their efficacy in 
this patient group. We searched the Cochrane Central Register of 
Controlled Trials until May 24, 2016, and PubMed from Jan 1, 1974, 
to May 24, 2016, with the terms “(azathioprine OR 
mercaptopurine OR thiopurine) AND Crohn’s AND (postoperative 
OR resection OR hemicolectomy OR ileectomy OR surgical 
procedures OR surgery) AND trial”, with no language restrictions. 
We identified three previous systematic reviews with 
meta-analyses comparing thiopurines with either placebo or 
mesalazine: two published by the Cochrane Collaboration and one 
by another group. The two Cochrane reviews differed in their 
choice of timepoint to assess outcome and in their handling of loss 
to follow-up. The earlier [A: the earlier Cochrane review?] review 
compared clinical recurrence at a standard time of 12 months 
across all studies and used the number of clinical relapses. [A: used 
the number of clinical relapses as what? The measure of clinical 
recurrence?] Clinical relapse differed significantly between 
thiopurines and placebo (risk ratio 0·59, 95% CI 0·38–0·92 
favouring thiopurines). The more recent Cochrane meta-analysis 
used the end of study, which varied between 1 year and 2 years, and 
regarded anyone who did not complete the study as a treatment 
failure. This study reported a benefit for thiopurines compared with 
placebo (risk ratio 0·74, 95% CI 0·58–0·94). The Grading of 
Recommendations Assessment, Development and Evaluation [A: 
correct expansion of GRADE?] score for the evidence was low. 
No further published randomised controlled trials were identified 
that compared thiopurines with placebo since the most recent 
Cochrane [A: correct?] meta-analysis. [A: what did the third 
meta-analysis show?]
Added value of this study
TOPPIC is, to our knowledge, the largest randomised 
controlled study of thiopurines for postoperative prevention 
of Crohn’s disease, and the largest interventional study of any 
kind for this indication, with 240 patients enrolled. We found 
no significant difference between mercaptopurine and 
placebo for the primary endpoint, a composite of clinical 
recurrence of Crohn’s disease (Crohn’s Disease Activity Index 
>150 plus 100 point increase in score) and the need for 
anti-inflammatory rescue treatment or primary surgical 
intervention. [A: addition ok? We need to mention the 
primary outcome here] In a subgroup analysis, smoking was 
predictive of clinical recurrence within 3 years of surgery 
(pinteraction=0·018), and mercaptopurine was effective at 
preventing clinical recurrence only in patients who smoked 
[A:OK?]. [A: edits OK? stating “the most important” 
implies both that other factors in the subgroup analysis 
showed significant differences between groups and that 
the subgroups were compared with one another]
Implications of all the available evidence
From our data, combined with those included in previous 
Cochrane meta-analyses, we calculated risk ratio of 0·57 
(0·38–0·85) in favour of mercaptopurine (appendix p 11). [A: 
0·58, 0·41–0·82 according to appendix p 11. Which is 
correct?] We confirm that smoking affects the clinical course of 
Crohn’s disease, as well as response to treatment, whereas no 
differences were reported by age, sex, or a history of previous 
surgery. The risk of recurrence in smokers was the most 
consistent finding in Buisson and colleagues’ review, with an 
odds ratio of 2·0. Smoking cessation should be a priority in 
patients with Crohn’s disease after surgery.
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delay postoperative clinical recurrence of Crohn’s disease 
in patients needing anti-inflammatory rescue treatment 
or surgery. [A: edited to describe only the primary aim; 
secondary objectives moved to Outcomes section]
Methods 
Study design and patients 
TOPPIC was a randomised, placebo-controlled, double-
blind study done at 29 secondary and tertiary UK 
hospitals. The study was approved by the Scotland ‘A’ 
Research Ethics Committee. The full protocol is available 
online.
Patients aged at least [A: correct? (as in your protocol, 
rather than patients aged older than 16)] 16 years 
(Scotland) or 18 years (England and Wales) who had a 
diagnosis of Crohn’s disease and an ileo-colic or small 
bowel resection within the preceding 3 months were 
eligible for inclusion.12 [A: please clarify why ref 12 is 
relevant to this sentence. Did you use Lennard-Jones’ 
definition of Crohn’s disease?] Key exclusion criteria 
were [A: correct that these are just the key exclusion 
criteria and others are listed in the appendix?]residual 
active Crohn’s disease present after surgery, known 
intolerance or hypersensitivity to thiopurines, known 
need for further surgery, strictureplasty alone, formation 
of a stoma, active or untreated malignancy, absent 
thiopurine methyltransferase activity, substantial 
abnormalities of liver function tests or full blood count, 
and pregnancy. The appendix (p 4) lists all inclusion and 
exclusion criteria. Before randomisation, postoperative 
infections were treated and existing treatments for 
Crohn’s disease stopped [A: was there any wash-out 
period for existing treatments or was mercaptopurine 
begun immediately?]. The protocol was amended [A: 
please specify exact date] to include patients successfully 
treated for a malignancy and in remission for at least 
5 years and to exclude those receiving treatment for 
active Crohn’s disease at random allocation. All patients 
provided written informed consent. [A: when? Before 
enrolment?]
Randomisation and masking 
Patients were randomly assigned (1:1) to mercaptopurine 
or placebo using a computer-generated web-based 
randomisation system managed by the Edinburgh 
Clinical Trials Unit (University of Edinburgh, Edinburgh, 
UK) and stratified according to smoking status at 
baseline and recruiting site (block sizes of two or four). 
Patients’ details were entered into the randomisation 
system before random allocation and were concealed at 
randomisation. Patients and their carers and physicians 
were masked to the treatment allocation. Blood 
monitoring results were reviewed by an independent 
central clinician [A: one of the authors? If so, please 
provide initials] masked to treatment allocation and to 
mean corpuscular volume results. [A: How was masking 
achieved? (Eg, use of tablets identical in appearance)] 
The appendix (p 5) details the dose reduction algorithm. 
To protect masking, investigators were informed that 
sham dose reductions were planned for patients on 
placebo. However, on the advice of the data monitoring 
committee, sham dose reductions did not occur; the 
investigators were not informed of this.
Procedures 
Patients received once daily mercaptopurine, at a dose of 
1 mg/kg body weight rounded to the nearest 25 mg, or 
placebo [A: orally?]. Patients with low thiopurine 
methyltransferase activity were prescribed half the 
normal dose.
Baseline assessments included [A: or “were”? ie, is this 
a complete list of prespecified baseline assessments?]
Crohn’s Disease Activity Index (CDAI); patient-reported 
outcome measures, including the Inflammatory Bowel 
Disease Questionnaire (IBDQ); a physical examination; 
and a blood sample for 6-thioguanine nucleotide 
concentrations (6-thioguanine and 6-methyl-
mercaptuprine). We also took additional blood samples 
for genetic and serological analysis and will report those 
results separately. Treatment was planned for 3 years, 
with dose adjusted for changes in bodyweight. The 
appendix (p 6) describes which procedures were done at 
which timepoints. Blood monitoring was done weekly 
for the first 6 weeks and thereafter at 6-weekly intervals. 
Patients with abnormal results had a dose reduction, 
temporary cessation, or cessation as per a study 
algorithm (appendix p 4). Patients with acute [A: OK? If 
not, please clarify “Profound” in this context] nausea or 
persistent influenza-like symptoms also received a dose 
reduction, according to the protocol. If abnormal 
parameters improved after a temporary cessation, 
treatment was recommenced at a lower dose. At each 
study visit, the following data were collected: CDAI, 
physical examination, concomitant medications, and 
patient-reported outcomes, including the IBDQ 
(appendix p 6). Samples for assay of faecal calprotectin, 
6-thioguanine, and 6-methylmercaptuprine were 
collected at randomisation and weeks 13, 49, 103, and 
157. [A: correct?] Faecal samples were stored on site at 
–80°C and then shipped on dry ice to a central laboratory 
(Gastrointestinal Laboratory, Western General Hospital, 
Edinburgh, UK) for analysis with the 
CALPRO Calprotectin ELISA test (ALP; NovaTec 
Immundiagnostica, Frankfurt, Germany). Samples were 
stored in a freezer until the patient exited the study, and 
all samples for an individual were then tested [A: OK? If 
not, please clarify “run”] at the same time. The Edinburgh 
laboratory has a coefficient of variation of 10% for faecal 
calprotectin (based on assessments of the entire sample 
processing pipeline). 6-thioguanine and 6-methyl-
mercaptuprine were analysed by the Viapath Purine 
Research Laboratory [A: please specify location]; 
thioguanine nucleotides and methylated mercaptopurine 
nucleotides were hydrolysed to the base by boiling in 
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acid [A: which acid?] and the bases (thioguanine and 
methylmercaptopurine) measured by ultraviolet 
absorption with separation on an ultra-performance 
liquid chromatography [A: correct expansion of UPLC?] 
system. Colonoscopy was done at 49 and 157 weeks after 
randomisation.
Outcomes 
The composite [A: OK? to distinguish from the secondary 
endpoint?] primary outcome was clinical recurrence, 
defined as a CDAI score of over 150 and a 100-point 
increase from baseline, and the need for anti-
inflammatory rescue treatment or primary surgical 
intervention. Secondary outcomes were clinical 
recurrence, defined as reaching either of the individual 
components of the primary outcome (ie, either a CDAI 
score of >150 and a 100-point increase from baseline, or 
the need for anti-inflammatory rescue treatment or 
primary surgical intervention); endoscopic recurrence, 
defined as a Rutgeerts score of at least i2; Crohn’s Disease 
Endoscopic Index of Severity (CDEIS) score;13,14 and 
quality of life, measured by changes in IBDQ scores.[A: 
in the statistical analysis section you also mention EQ-
5D. Should this be added here? Please clarify] Adverse 
events were assessed by investigators at [A: OK? If not, by 
who?] the participating sites in accordance with the trial 
protocol. [A: using what scale? CTCAE? What version?]
Statistical analysis 
A sample size of 234 patients was needed to give 80% 
power to detect a reduction in the frequency of recurrence 
from 50% in the placebo group to 30% in the treatment 
group by 3 years at the 5% level of significance.
Analyses were by intention to treat. For the primary 
analysis, we used a Cox proportional hazards model with 
terms for treatment and the variables on which the 
randomisation was stratified (smoking status and 
recruitment site), adjusted for baseline values of 
previous treatment with mercaptopurine and previous 
treatment with azathioprine. We present adjusted and 
unadjusted Cox proportional hazard ratios (HRs) for the 
comparison of mercaptopurine versus placebo 
(reference), with a HR of less than one suggesting a 
treatment effect in favour of mercaptopurine. For both 
primary and secondary outcomes, the adjusted analysis 
was judged to be the primary analysis. We did predefined 
subgroup analyses of the primary and secondary 
outcomes to assess treatment effect in terms of previous 
medical treatment, previous surgery, smoking status, 
duration of disease, and age at diagnosis. The interaction 
between subgroup and treatment was included in the 
Cox regression model to establish whether the treatment 
effect differed by subgroup.
We compared endoscopic recurrence between treatment 
groups using a χ² test. CDEIS results at week 157 were 
compared between treatment groups using a t test [A: what 
kind of t test? (one or two-sided?)]. The same subgroups 
analysed for the primary and secondary outcomes were 
also analysed with respect to endoscopic recurrence and 
CDEIS scores [A: was this analysis prespecified? Please 
clarify]. We produced receiver operating characteristic 
(ROC) curves to calculate the diagnostic accuracy of faecal 
calprotectin to predict endoscopic recurrence and 
remission. The optimum cutoff point was calculated by 
maximising Youden’s J statistic. We incorporated faecal 
calprotectin and 6-thioguanine separately into a Cox 
proportional hazards model as time-varying covariates. 
Quality of life, as measured by the IBDQ, was analysed 
using a change from baseline repeated measures ANCOVA 
to assess the effect of treatment over time for the overall 
mean IBDQ score and also the overall total IBDQ score. 
Quality of life as measured by the EQ-5D system was 
summarised by treatment group across study visits.
We excluded missing data from any formal statistical 
analyses, with the exception of statistical analysis of 
IBDQ data, for which we used several imputation 
techniques [A: which techniques?]. A data monitoring 
committee oversaw the trial. Data were analysed in SAS 
version 9.4.
This trial is registered with the International Standard 
Randomised Controlled Trial Register (ISRCTN89489788) 
and the European Clinical Trials Database (EudraCT 
number 2006-005800-15).
Role of the funding source 
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to 
all the data in the study and had final responsibility for 
the decision to submit for publication.
Figure 1: Trial profile
[A: figure redrawn to match standard style. Please check information is correct (we do not include primary or 
secondary outcome data in the trial profile)] [A1: please clarify your meaning here. What was found on the 
blood tests that resulted in exclusion?]
128 assigned to mercaptopurine
240 randomly assigned
88 ineligible or declined participation
328 patients screened
66 discontinued
 8 withdrew
 7 lost to follow-up
 39 adverse events
 12 safety blood test [A1] 
128 included in primary analysis
112 assigned to placebo
70 discontinued
 13 withdrew
 9 lost to follow-up
 1 died
 41 adverse events
 6 safety blood test [A1] 
112 included in primary analysis
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Results 
Between June 6, 2008, and April 23, 2012, 328 patients 
were screened at 29 centres (appendix p 7), 240 of whom 
met eligibility criteria, consented to inclusion, and were 
randomly assigned [A: how many were enrolled?]: 128 to 
mercaptopurine and 112 to placebo (figure 1). [A: how did 
16 more patients end up being assigned to 
mercaptopurine than placebo, given the 1:1 allocation 
ratio?] All patients received at least one dose of study 
drug. 146 (61%) were women and 55 (23%) were smokers 
(table 1). Baseline characteristics were similar between 
study groups (table 1). 104 (43%) of 240 patients received 
study drug at the initial dose [A: added to match 
statement in Discussion] for the entire 3-year treatment 
period. The mean treatment period was 22·6 months [A: 
SD?]: 23·4 months [A: SD?] in the mercaptopurine group 
versus 21·8 months [A: SD?] in the placebo group. 
50 (39%) of 128 patients in the mercaptopurine group 
and 18 (16%) of 112 in the placebo group had a dose 
reduction in accordance with the trial protocol. Study 
drug was discontinued in 66 (52%) of 128 patients in the 
mercaptopurine groups versus 70 (63%) of 112 in the 
placebo group for the following reasons: adverse events 
(59%), blood monitoring results [A: what about these 
results led to discontinuation?] (13%), early withdrawal 
(15%), loss to follow-up (12%), and death (1%). [A: please 
give numbers in each group for every percentage] The 
appendix (p 8) summarises data completeness for the 
study visits. Median follow-up was 36 months 
(IQR 27·5–36) [A: Please give all data either as whole 
numbers or to 1 dp] in the mercaptopurine group and 
36 months (19·5–36) [A: Please give all data either as 
whole numbers or to 1 dp]in the placebo group.
The composite primary endpoint of clinical recurrence 
of Crohn’s disease and the need for anti-inflammatory 
rescue treatment or primary surgical intervention occurred 
in 42 (18%) of 240 patients: [A: edited to distinguish from 
secondary clinical recurrence endpoint. OK?] 16 (13%) of 
128 in the mercaptopurine group versus 26 (23%) of 112 in 
the placebo group (adjusted HR 0·535 [A: please give to 2 
dp], 95% CI 0·27–1·06; p=0·07; unadjusted HR 0·53, 
95% CI 0·28–0·99; p=0·046; figure 2). All 42 patients met 
the CDAI trigger [A: what do you mean by “met the CADI 
trigger”?] and had rescue treatment, five (12%) of whom 
Mercaptopurine 
(n=128)
Placebo (n=112)
Sex
Female 79 (62%) 67 (60%)
Male 49 (38%) 45 (40%)
Age (years)
Mean (SD) 39·2 (12·8) 38·2 (13·4)
Median (IQR) 38 (28–50) 36 (28–48)
Range 17–67 17–75
Age at diagnosis
≤40 years 103 (80%) 87 (78%)
>40 years 25 (20%) 23 (21%)
Unknown 0 2 (2%)
Present smoker
Yes* 29 (23%) 26 (23%)
No 99 (77%) 86 (77%)
Duration of Crohn’s disease
≤1 year 37 (29%) 41 (37%)
>1 year 91 (71%) 69 (62%)
Unknown 0 2 (2%)
Duration of Crohn’s disease (years)†
Mean (SD) 7·7 (9·7) 7·6 (9·5)
Median (IQR) 3 (0–11) 4 (0–11)
Range 0–39 0–47
Crohn’s disease location‡
Ileal 54 (42%) 39 (35%)
Colonic 4 (3%) 2 (2%)
Ileocolonic 70 (55%) 70 (63%)
(Table 1 continues in next column)
Mercaptopurine 
(n=128)
Placebo (n=112)
(Continued from previous column)
Previous treatments
Mercaptopurine‡
Yes 14 (11%) 5 (4%)
No 114 (89%) 106 (95%)
Azathioprine‡
Yes 80 (63%) 47 (42%)
No 48 (38%) 64 (57%)
Either thiopurine‡
Yes 81 (63%) 50 (45%) [A1]
No 47 (37%) 61 (54%) [A1]
Infliximab§
Yes 21 (16%) 15 (13%)
No 104 (81%) 96 (86%)
Methotrexate‡
Yes 8 (6%) 7 (6%)
No 120 (94%) 104 (93%)
Other corticosteroids‡
Yes 97 (76%) 79 (71%)
No 31 (24%) 32 (29%)
Any immunosuppressants‡
Yes 112 (88%) 86 (77%)
No 16 (13%) 25 (22%)
Previous surgery‡
Yes 46 (36%) 28 (25%)
No 82 (64%) 83 (74%)
Data are number (%), unless otherwise specified. Some percentages do not add up 
to 100 because of rounding. *Smoked >1 cigarette per day at study entry. †Data 
missing for two patients in the placebo group. ‡Data missing for one patient in 
the placebo group. §Data missing for three patients in the mercaptopurine group 
and one in the placebo group. [A1: percentage updated based on n/N×100]
Table 1: Demographics and baseline characteristics before 
randomisation
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subsequently went on to have surgery. 15 (27%) of 
55 smokers had a clinical recurrence, three (10%) of 29 in 
the mercaptopurine group and 12 (46%) of 26 in the 
placebo group (HR 0·13, 95% CI 0·04–0·46), compared 
with 27 (15%) of 185 non-smokers, 13 (13%) of 99 in the 
mercaptopurine group and 14 (16%) of 86 in the placebo 
group (0·90, 0·42–1·94; pinteraction[A: correct?]=0·018; 
figure 3). The number needed to treat (NNT) [A: Please 
add a description of NNT methods to the Methods section 
and specify whether or not this was a preplanned analysis] 
was calculated as three for smokers (95% CI 1·7–7·3) [A: is 
this for benefit or harm? And why do you only give one for 
smokers but both for non-smokers?] and 31 for non-
smokers (95% CI NNTbenefit 7·5 to ∞ to NNTharm 14·1) across 
the entire follow-up period. Previous exposure to 
treatment, previous surgery, thiopurine status, duration of 
disease, and age at diagnosis had no effect on the response 
to study drug (figure 3).
34 (27%) of 128 patients in the mercaptopurine group 
versus 40 (36%) of 112 in the placebo group experienced 
the secondary endpoint of clinical recurrence, defined as 
a CDAI rise or need for rescue treatment or surgery 
(adjusted HR 0·74, 95% CI 0·44–1·23; p=0·24 [A: 0·21 in 
figure 4. Which is correct?]). In subgroup analyses, 
mercaptopurine reduced recurrence in smokers only 
(pinteraction=0·033; figure 4).
Of the 208 patients who remained in the study 49 weeks 
after randomisation, 172 attended for colonoscopy, and a 
Rutgeerts score was available for 168. [A: please provide 
numbers in each group] Of these, 121 (72%) had some 
form of endoscopic recurrence (score >i0). [A: please 
provide numbers in each group] Of the 161 patients who 
Figure 2: Kaplan-Meier plot of the primary outcome [A: title OK?]
[A: Data for mercaptopurine are shown for longer than placebo. Is this because they show up until the point 
at which all patients had exited the trial? If so, what is the vertical line for at the end of the mercaptopurine 
data? Can this be deleted?]
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Figure 3: Subgroup analyses of primary outcome [A: title OK?]
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remained in the study at week 157 after randomisation, 
128 underwent a colonoscopy, and a Rutgeerts score was 
available for 124. [A: please provide numbers in each 
group] Of these, 95 (77%) had some form of endoscopic 
recurrence (score >i0). [A: please provide numbers in 
each group] [A: deleted definition of endoscopic 
recurrence secondary endpoint to avoid repetition] 29 
(33%) of xx patients in the mercaptopurine group and 28 
(39%) of xx [A: please specify denominators for each 
group] in the placebo group had endoscopic recurrence 
with a Rutgeerts score of i2 or greater (adjusted odds 
ratio 0·66, 95% CI 0·26–1·67; p=0·38). We noted a 
similar pattern at week 49. [A: Please provide data in the 
appendix and OR, 95% CI and p value here] Week 157 
CDEIS scores did not differ significantly between groups. 
[A: Please provide data in the appendix and OR, 95% CI 
and p value here] Similarly, none of the CDEIS subgroup 
analyses showed a significant interaction with treatment. 
[A: data not shown? And what about the subgroup 
analyses for endoscopic recurrence, mentioned in the 
Methods section?]
Of the 168 patients who had a Rutgeerts score calculated 
at week 49, faecal calprotectin concentrations were 
available in 126 patients. [A: how many in each group?] 
Of the 124 patients who had a Rutgeerts score calculated 
at week 157, faecal calprotectin concentrations were 
available in 88 patients (appendix p 12). [A: how many in 
each group?] These data were combined to generate ROC 
curves to examine test accuracy at predicting endoscopic 
recurrence and remission. In both scenarios, the faecal 
calprotectin measurement proved to be a poor [A: in 
what way? Inaccurate?] test, with an area under the curve 
of 0·7[A: please provide to 2 dp] (95% CI 0·63–0·77) for 
recurrence and 0·66 (0·58–0·75) for remission. [A: 
correct?] Selecting a faecal calprotectin concentration of 
50 µg/g (the manufacturer’s [A: who? Please specify 
company and location] cutoff) to predict endoscopic 
recurrence produced a sensitivity of 84·4% (95% CI 
77·0–91·9), specificity of 44·4% (35·6–53·1), positive 
predictive value of 52·4% (44·3–60·5), and negative 
predictive value (NPV) of 79·7% (70·2–89·2). Increasing 
the cutoff concentration to 100 µg/g produced a sensitivity 
of 72·2% (95% CI 63·0–81·5), specificity of 62·1% 
(53·6–70·6), positive predictive value of 58·0% 
(48·9–67·2), and NPV of 75·5% (67·1–83·8). The NPV 
for the prediction of endoscopic remission with a faecal 
calprotectin concentration of 50 µg/g was 81·4% (95% CI 
75·0–87·7) and with a concentration of 100 µg/g it was 
83·9% (77·1–90·7; appendix p 9). Analysis of faecal 
calprotectin as a time-varying covariate suggested that, 
for every 100-unit increase in faecal calprotectin, the HR 
for the primary endpoint (data available for 31 [74%] of 
42 patients who reached the primary endpoint) increased 
by 18% (HR 1·18, 95% CI 1·08–1·28; p=0·0002).
Figure 4: Subgroup analyses of secondary outcome of clinical recurrence
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102 (92%) of 111 patients had 6-thioguanine nucleotide 
concentrations measured at week 49, and 64 (72%) of 
89 who remained on mercaptopurine had concentrations 
measured at week 157. 6-thioguanine nucleotide 
concentrations were grouped according to the target 
therapeutic range (235–450 pmol per 8 × 10⁸ red blood 
cells [A: correct expansion of RBC?]). At week 49, 61 (60%) 
of 102 patients had subtherapeutic concentrations, versus 
40 (63%) of 64 at week 157 (appendix p 13). [A: was this 
difference significant? Please provide HR, 95% CI, and p 
value] In the corresponding time-varying covariate 
analysis of 6-thioguanine nucleotide concentrations in 
patients receiving mercaptopurine, the association with 
the primary outcome was not significant (HR 0·80, 
95% CI 0·565 [A: please give to 2 dp]–1·13; p=0·21).
IBDQ data were available for 203 (85%) of 240 randomly 
assigned patients at week 49 and 155 (65%) at week 157. 
[A: please provide numbers per group] Overall mean or 
total IBDQ scores did not differ significantly between 
groups. [A: please provide data (ie, OR/HR, 95% CI, and 
p value)] [A: where are these data shown? Could they be 
included in the appendix?]
The incidence and types of adverse events were similar 
in the mercaptopurine and placebo groups (table 2 and 
appendix p 10). Adverse events caused discontinuation of 
treatment in 80 (33%) of 240 patients: 39 (30%) of 128 in 
the mercaptopurine group versus 41 (37%) of 112 in the 
placebo group. Of the 1747 [A: 1745 according to 
supplementary table 7. Please check] reported adverse 
events, four (<1%) were malignancies (three in the 
mercaptopurine group and one in the placebo group: 
basal cell carcinoma, breast cancer, and two cases of 
lentigo maligna), [A: which in which group?] and one 
patient on placebo died of ischaemic heart disease. 171 
(18%) of 947 events in the mercaptopurine group and 184 
(23%) of 798 in the placebo group were infections. 
Mercaptopurine was temporarily stopped in 32 patients 
on mercaptopurine because of blood test values [A: that 
showed what?] or other side-effects. Placebo was 
temporarily discontinued in 35 patients. [A: for what 
reasons?] [A: deleted repetition of dose reduction details]
14 pregnancies were reported during the course of the 
trial, with 12 healthy outcomes. [A: successful births?] 
One spontaneous abortion occurred at about 21 weeks 
gestation [A: in which group?] and one congenital 
anomaly (heart murmur, septal defect, and 
hydrocephalus) occurred in a patient [A: or fetus?] in the 
placebo group.
In a post-hoc analysis, complete endoscopic remission 
(Rutgeerts score i0) was maintained in proportionally 
more patients on mercaptopurine than placebo at both 
week 49 (30% vs 14%) and week 157 (23% vs 13%; [A: 
rounding correct?] appendix pp 14–15 [A: any statistical 
analysis available? Ie, p value]). In a [A: post-hoc?]
subgroup analysis, mercaptopurine was more effective at 
preventing endoscopic recurrence in patients with 
previous thiopurine exposure (odds ratio 0·25, 95% CI 
0·09–0·70) than in thiopurine-naive patients (3·00, 
1·00–9·04; p=0·001) [A: are these data shown in any 
citeable figure or table? Please add “(data not shown)” if 
not]. Endoscopic recurrence, defined as Rutgeerts score 
greater than i0 [A: i0 correct?] (ie, anything other than 
complete remission), was present in 58 (64%) of 
91 patients in the mercaptopurine group versus 62 (82%) 
of 76 in the placebo group at week 49 (p=0·01), and in 
47 (70%) of 67 in the mercaptopurine group versus 
Mercaptopurine (n=128) Placebo (n=112)
Mild Moderate Severe Total Mild Moderate Severe Total
Cancers 0 2 (2%) 0 2 (2%) 0 0 1 (1%) 1 (1%)
Abnormal liver function test 0 4 (3%) 0 4 (3%) 0 5 (4%) 0 5 (4%)
Gastrointestinal symptoms
Abdominal pain 15 (12%) 32 (25%) 19 (15%) 66 (52%) 10 (9%) 42 (38%) 15 (13%) 67 (60%)
Constipation or diarrhoea 12 (9%) 19 (15%) 6 (5%) 37 (29%) 7 (6%) 23 (21%) 7 (6%) 37 (33%)
Nausea or vomiting 13 (10%) 24 (19%) 8 (6%) 45 (35%) 12 (11%) 16 (14%) 2 (2%) 30 (27%)
Other 14 (11%) 16 (13%) 4 (3%) 34 (27%) 12 (11%) 16 (14%) 0 28 (25%)
Headache 9 (7%) 17 (13%) 0 26 (20%) 6 (5%) 11 (10%) 3 (3%) 20 (18%)
Infections 31 (24%) 45 (35%) 5 (4%) 81 (63%) 24 (21%) 38 (34%) 6 (5%) 68 (61%)
Joint pain or arthralgia 13 (10%) 23 (18%) 4 (3%) 40 (31%) 8 (7%) 26 (23%) 2 (2%) 36 (32%)
Other [A1] 22 (17%) 55 (43%) 8 (6%) 85 (66%) 18 (16%) 35 (31%) 9 (8%) 62 (55%)
Pain 7 (5%) 8 (6%) 3 (2%) 18 (14%) 4 (4%) 10 (9%) 3 (3%) 17 (15%)
Pancreatitis 0 1 (1%) 0 1 (1%) 0 0 1 (1%) 1 (1%)
Rash 14 (11%) 9 (7%) 1 (1%) 24 (19%) 12 (11%) 2 (2%) 0 14 (13%)
Worsening of Crohn’s disease 6 (5%) 13 (10%) 5 (4%) 24 (19%) 3 (3%) 20 (18%) 6 (5%) 29 (26%)
[A: who were adverse events categorised? CTCAE? Which version?] Data are number of patients with one or more adverse event in that category. Patients who had more 
than one adverse effect in the same category but different severity are counted in the most severe category. [A1: please specify]
Table 2: Adverse events
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48 (84%) of 57 in the placebo group at week 157 (p=0·07). 
[A: are these data shown in any citeable figure or table? 
Please add “(data not shown)” if not]
Discussion 
To our knowledge, this is the largest randomised, double-
blind study to assess the efficacy of mercaptopurine in 
the prevention of postoperative Crohn’s disease. The 
primary outcome, a composite of clinical recurrence of 
Crohn’s disease (Crohn’s Disease Activity Index >150 plus 
100 point increase in score) and the need for anti-
inflammatory rescue treatment or primary surgical 
intervention, was reached by 13% of patients in the 
mercaptopurine group versus 23% in the placebo group 
(adjusted p=0·07); however, clinical recurrence was 
significantly more common in smokers, in whom 
mercaptopurine proved beneficial, with a NNT of three. 
The secondary outcome of endoscopic recurrence was 
recorded in a third of patients in each group, with no 
significant difference between groups; however, in a 
post-hoc analysis, mercaptopurine was significantly 
more effective than placebo at maintaining complete 
endoscopic remission. Although there was no significant 
difference in the prespecified primary clinical efficacy 
endpoint, the subgroup analyses provide relevant 
insights in terms of clinical prediction of response and 
outcome, and in terms of the challenges in assessing 
outcome by endoscopic or clinical criteria.
Findings form this study confirm that smoking affects 
the clinical course of Crohn’s disease, as well as response 
to treatment. Of the factors assessed, the primary 
endpoint was only significantly different between 
smokers and non-smokers, whereas no differences were 
reported by age, sex, or a history of previous surgery [A: 
add duration of disease, previous treatments, and 
thiopurine status here?]. The data highlight the 
importance of smoking cessation in disease management 
and support findings from previous studies15–17 that 
showed that surgical recurrence increases with the 
number of cigarettes smoked each day, and that smoking 
cessation reduces clinical and surgical recurrence. 
Treatment with mercaptopurine to delay or prevent 
postoperative recurrence is particularly effective in 
people who continue to smoke [A: which study are you 
referring to here?]; thus, in smokers, thiopurine 
treatment seems to be justified in the early postoperative 
period. In non-smokers, the data do not provide a 
sufficiently strong rationale for immediate initiation of 
treatment in the postoperative period. A considered 
approach involving colonoscopy in the first 6–12 months 
is likely to [A: OK? or “might”?] be beneficial in this 
group.
This study is one of the largest to report on endoscopic 
recurrence of Crohn’s disease, and is important for 
several reasons. First, the incidence of any endoscopic 
recurrence was 76% [A: Results state 77%. Which is 
correct?] at 3 years, which is similar to the 85% reported 
previously.13 Second, over a 3-year period, there was a 
poor association between endoscopic and clinical 
recurrence. [A: correct?] There are several possible 
explanations for this finding, and there is no consensus 
as to whether to prioritise clinical outcomes over 
endoscopic outcomes. Third, mercaptopurine seems to 
maintain complete endoscopic remission (i0), whereas 
using a cutoff score of at least i2 to define endoscopic 
recurrence revealed no difference between treatment and 
placebo groups. Fourth, our study is, to our knowledge, 
the largest comprehensive assessment of faecal 
calprotectin in postoperative Crohn’s disease. Using a 
cutoff of 50 µg/g, the NPV for recurrence was 79·7%, 
which decreased to 75·5% by increasing the cutoff to 
100 µg/g. The corresponding NPVs for the prediction of 
endoscopic remission were 81·4% and 83·9%, 
respectively. If mucosal integrity is the goal, these values 
might not [A: OK? or “are unlikely to”] provide the 
confidence to abandon endoscopic assessment. The 
performance of faecal calprotectin was poorer than 
reported in the POCER study (NPV of 94%).11 Reported 
differences between studies are probably due to 
differences in study methods, since in the POCER study, 
an endoscopic score of i2 was imputed for all missing 
values; no imputations were made in our study.
Several important factors should be considered when 
interpreting these findings. Based on existing data, 
power calculations estimated a 20% difference between 
mercaptopurine and placebo groups. Clinical recurrence 
rates were 23·2% in the placebo group and 12·5% in the 
treatment group: a difference of 10·7%. These rates are 
lower than those in studies by Hanauer and colleagues18 
(40% and 75% [A: what are these two percentages for—
treatment vs placebo?]) and Ardizzone and colleagues19 
(25%), on which the power calculations were based. This 
marked difference between recurrence rates is probably 
a result of differing primary outcome definitions; clinical 
scoring systems advocated to identify disease relapse in 
clinical trials such as CDAI have flaws, especially in the 
postoperative setting.20 We used a composite outcome 
that was based on a disease activity score (CDAI >150 
and a 100-point increase from baseline) and the need for 
medical treatment. In view of the difficulties of using the 
CDAI postoperatively, we judged this definition of 
clinical recurrence to be robust. An analysis of the 
individual items of the CDAI or the need for rescue 
treatment was part of the secondary outcomes and 
performed less effectively than the primary outcome. [A: 
what do you mean by “performed less effectively”? “was 
not significant”?] The Rutgeerts score attempts to make 
the assessment of endoscopic recurrence an objective 
exercise, but has never been prospectively validated.13 We 
selected a score of at least i2 as a secondary endpoint, in 
line with previous studies, including the study by 
Hanauer and colleagues.18 However, the limitations of 
this approach are well recognised; there is little 
difference between i1 (≤5 aphthous ulcers) and i2 
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(>5 aphthous ulcers or larger lesions confined to the 
anastomosis), and inter-observer variation is an issue. In 
a substudy21 of the TOPPIC trial, inter-observer 
agreement on 43 endoscopic images was measured by 
five investigators; complete agreement occurred in only 
79% of cases. Although centralised reading could 
overcome some of the inter-observer variation in 
endoscopic scoring in future studies, an alternative 
approach might be to regard complete mucosal healing 
as the preferred therapeutic target in Crohn’s disease, 
and to identify maintenance of endoscopic remission 
(i0) as the target in postoperative Crohn’s disease. A 
review of the scoring of endoscopic recurrence is 
warranted.
Optimum dosing in all patients was also difficult to 
achieve in the context of a double-blind study and a 
protocol-led dose adjustment strategy. Of the 240 patients, 
104 (43%) received treatment at the initial dose for the 
duration of the study. Data available at the end of the 
study show that about 60% of patients randomly assigned 
to mercaptopurine were on subtherapeutic doses, and a 
stronger treatment effect might have been noted had 
6-thioguanine nucleotide results been available to 
optimise the dose during the study. The rates of 
discontinuation of treatment and withdrawal or loss to 
follow-up in this study are similar to those in previous 
work. For example, Ardizzone and colleagues19 reported 
treatment discontinuations owing to adverse events in 15 
(11%) of xx patients in the azathioprine group versus six 
(4%) of xx in the mesalazine group, [A: please provide 
numbers] although data on treatment discontinuation 
within other trials are less transparent. [A: please clarify 
what you mean by “less transparent”, than what?] 
Analysis of these data was on an intention-to-treat basis 
and therefore the effect of the drug taken at full dose in 
an individual patient is likely to have been 
underestimated. In clinical practice, many patients 
taking thiopurines are likely to be [A: OK? or simply 
“are”?] under-dosed initially, but are identified on the 
basis of mean corpuscular volumes or, more recently, 
available metabolite testing.22
Adverse events were noted frequently in both groups 
but were generally mild. Rates of pancreatitis and 
malignancy were lower than expected. Unusually for a 
clinical trial, we did not remove patients who became 
pregnant during the trial, in-keeping with accepted 
clinical practice. We noted 14 pregnancies, with 12 healthy 
outcomes. No fetal malformations occurred in the 
mercaptopurine-treated group. Masked safety monitoring 
contributed to the validity of the results.
The strengths of this study include the double-blind 
design, the association [A: comparison?]of symptom 
scores with endoscopic findings, the assessment of faecal 
calprotectin in a large number of patients in the 
postoperative setting, and a demonstration of the 
potential usefulness of 6-thioguanine nucleotide 
concentrations in patient management. The study also 
included patients from 29 UK centres, both secondary 
and tertiary hospitals, which makes it generalisable [A: to 
the UK population?]. Limitations include the absence of 
therapeutic drug monitoring with dose adjustment, 
missing colonoscopy data in 20% of eligible patients, and 
the absence of centralised endoscopy reading. 
Furthermore, we included CDAI measurement within 
the primary outcome even though it has been previously 
criticised in this setting. The 36-item Short Form quality 
of life instrument underwent internal text changes at the 
time of trial start-up. The reporting of these results was 
deemed not to be compliant with 36-item Short Form 
licensing terms and these results are therefore not 
presented.
A definitive study of postoperative prevention of 
Crohn’s disease has proved difficult to undertake. [A: 
edits OK?] The PREVENT study23 was terminated early 
because of small numbers of patients reaching the 
primary outcome. The PREVENT study23 had selective 
inclusion criteria, and no difference was reported in 
clinical relapse between those on infliximab and those on 
placebo at week 76, although an endoscopic effect was 
noted. A smaller study24 that compared early azathioprine 
initiation with azathioprine driven by endoscopic 
findings at week 26 was stopped after 6 years because of 
slow recruitment, with no meaningful conclusions [A: 
meaning the study was underpowered to draw any 
conclusion?]. Although our study was underpowered to 
detect the reported treatment effect, and many patients 
were under-dosed with mercaptopurine, our data 
nonetheless provide some evidence of efficacy of 
mercaptopurine in the context of postoperative 
prevention. Indeed, a meta-analysis of these data with 
the two other randomised placebo-controlled trials of 
thiopurines in the postoperative setting15,18 shows a 
significant reduction in postoperative clinical relapse at 
12 months (relative risk 0·57, 95% CI 0·38–0·85; 
appendix p 11). [A: 0·58, 0·41–0·82 according to appendix 
p 11. Which is correct?] Taken with the other recent data, 
our study helps to make progress towards a treatment 
algorithm for all patients after surgery for Crohn’s 
disease, with smoking habit the key determinant 
affecting management.
Several areas now require further clinical studies, [A: 
edits OK?] including putative mechanisms for the effect 
of smoking on Crohn’s disease,25 and smoking 
intervention studies. The efficacy and safety of 
mercaptopurine compared with anti-tumour-necrosis-
factor (TNF) as postoperative preventative treatment is a 
key issue to investigate. At present, anti-TNF treatment is 
reserved for patients who are intolerant or unresponsive 
to thiopurine, but the safety, efficacy, and cost of these 
drugs is under continuous reassessment. Endoscopic 
findings and faecal calprotectin remain important 
components of disease assessment, but the exact 
parameters that best define postoperative recurrent 
disease remain to be elucidated.
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